An HIV-positive man in Britain became the second known adult worldwide to be cleared of the AIDS virus after he received a bone marrow transplant from an HIV resistant donor, his doctors said.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation aimed at lowering the cost of prescription drugs for U.S. consumers.
A new report indicates that the so-called “Brexit” will have a negative impact on healthcare in the United Kingdom.
Antibiotics are used far more in some countries than in others, a survey by the World Health Organization showed, suggesting that urgent action was needed to slash unnecessary consumption of the medicines.
The number of new clinical trials started in Britain during 2017 was 25 percent lower than the average for 2009-2016, as anxiety about Brexit’s impact on future medicines regulation made companies hesitate about running studies in the country.
Denmark’s Novo Nordisk will cut around 250 jobs in the United States, but the drugmaker will also hire an as-yet undetermined number of staff to new positions.
Novo Nordisk said the world’s top maker of diabetes drugs will lay off 400 staff in Denmark and China as part of a broader restructuring of the company’s research and development organization.
Almost half of all European-registered clinical trials have breached EU rules by failing to report results, according to a published analysis.
Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.